Key result
17β-estradiol prevents PCSK9-dependent LDLR degradation in HepG2 cells through GPER activation, leading to increased LDL uptake.
Why the study?
Little is known about how estrogen alters PCSK9-mediated LDLR degradation in liver cells.
Population
Cultured HepG2 cells
Comparison
17β-estradiol incubation with or without PCSK9 and GPER antagonist G15
Design
In vitro study
Authors
Loading...
May explain sex differences in LDL metabolism; hypothesis-generating and requires in vivo confirmation before clinical consideration.
This in vitro study demonstrates a mechanistic pathway by which estrogen regulates LDLR levels via GPER activation, preventing PCSK9-dependent LDLR degradation and potentially explaining lipid profile differences in pre- and postmenopausal women.
Fu et al. (2020) studied PCSK9-mediated LDLR degradation. 17β-estradiol (βE2) vs. Absence of βE2 was evaluated on PCSK9-mediated LDLR degradation. 17β-estradiol prevents PCSK9-dependent LDLR degradation in HepG2 cells through GPER activation, leading to increased LDL uptake.